Physician profile
Hutton Brown
NPI 1023571163
$5,978.83
in general payments reported to CMS, 2019-2025
20 companies · $2,994 in 2025
The $2,994 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $411 · 2023: $1,336 · 2024: $1,238 · 2025: $2,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,548 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,547.75 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,484.76 | 2025 | Rapiblyk |
| Pfizer INC. | $651.59 | 2023-2025 | |
| Csl Behring | $633.27 | 2022-2025 | Kcentra |
| E.R. Squibb & Sons, L.L.C. | $470.51 | 2022-2025 | Eliquis, Camzyos |
| Alexion Pharmaceuticals, INC. | $434.85 | 2023-2025 | Ultomiris |
| Ferring Pharmaceuticals INC. | $352.54 | 2023-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $260.85 | 2022-2025 | Dificid, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.99 | 2023-2025 | Jardiance |
| Shionogi INC | $230.71 | 2022-2024 | Fetroja |
| Abbvie INC. | $229.49 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $197.11 | 2022-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.27 | 2022-2025 | Xifaxan |
| Inspire Medical Systems, INC. | $179.70 | 2025 | Inspire |
| Vifor Pharma, INC. | $147.17 | 2022-2023 | Veltassa |
| Vertex Pharmaceuticals Incorporated | $80.64 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $76.17 | 2025 | Vowst |
| Astrazeneca Pharmaceuticals Lp | $40.79 | 2022-2023 | Lokelma |
| Novartis Pharmaceuticals Corporation | $31.86 | 2023 | |
| Insmed, INC. | $26.15 | 2023 | Arikayce |
| Melinta Therapeutics, LLC | $15.41 | 2024 | Rezzayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hutton Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.